Melatonin Modulates the Immune System Response and Inflammation in Diabetic Rats Experimentally-Induced by Alloxan

Abstract
Diabetes mellitus (DM) is a metabolic disease, which causes an increase in the proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin 1β (IL-1β), and also proliferation of monocyte chemotactic protein. In the present study, the potential effects of melatonin on proinflammatory cytokines, hematological values, and lymphoid tissues were investigated in diabetic rats. In the study, 36 male rats were randomly divided into 4 groups as follows: Control, Mel (melatonin), DM, and DM-Mel. For 15 days, an isotonic saline solution was given to the Control and DM groups; melatonin was administered to the Mel and DM-Mel groups intraperitoneally. At the end of the study, all animals were sacrificed by drawing the blood from their hearts under deep anesthesia. Samples of the spleen, thymus, and lymph nodes were fixed in 10% formaldehyde for histologic analysis. Increases in proinflammatory serum cytokine concentrations, mast cells, and total white blood cell counts as well as tissue destruction in the lymphoid organs were determined in the DM group via biochemical, hematological, and histologic analyses. However, the findings for the DM-Mel group revealed decreases in serum IL-1β concentration and mast cell densities, and destructions in lymphoid tissues by the melatonin administration. The present study suggests that melatonin treatment may control immune system regulation and inhibit the production of proinflammatory cytokines and tissue mast cell accumulation by preventing the destruction of lymphoid organs in the diabetic process.

Introduction
Diabetes mellitus (DM) is characterized by high blood glucose, polyuria, polydipsia, and polyphagia accompanied by insulin secretion from pancreatic β cells that are insufficient to maintain blood glucose homeostasis [1]. DM is divided into 2 etiopathogenic groups. Type 1 diabetes mellitus (T1DM) is defined in the first category and is caused by the autoimmune destruction of β cells. Type 2 diabetes mellitus (T2DM) is produced by conditions that reduce insulin sensitivity and negatively affect β-cell activities [1,2]. DM results in hyperglycemia, neuropathy, nephropathy, and retinopathy due to insulin deficiency or resistance and high blood glucose [2]. There is also some evidence suggesting that diabetics have a deficiency in inflammatory control [3]. Cytokines are chemical substances that have an important role in the immune response of many diseases, including type 1 diabetes [4]. Proinflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), promote the destruction of pancreatic endocrine islets via islet-infiltrating immune cells [5]. It has been demonstrated that many functional abnormalities associated with diabetes can partially contribute to failure in appropriate inflammatory responses. Some researchers have suggested the concurrent occurrence of allergic disorders in T1DM [6]. In addition, it has been proposed that mast cells and eosinophil accumulation are decreased in the pleural cavity due to allergic reactions in diabetes mellitus patients [7]. Mast cells (MCs) have central effector and regulatory roles in inflammatory diseases (autoimmunity, allergic diseases, and parasitic infections) [8]. They are located in many tissues in the body, such as the airways, skin, gastrointestinal tract, and lymphoid tissues, and have the ability to release proinflammatory and immunoregulatory mediators [6]. The autoimmune response against islet β cells is believed to result from a disorder of immunoregulation. Macrophages...
produce proinflammatory cytokines (IL-1β and TNF-α). IFNγ exert their cytotoxicity on β cells in large part by inducing the formation of oxygen free radicals, nitric oxide, and peroxynitrite in the β cells themselves [9]. TNF-α has an important key role in the pathogenesis of T2DM [10]. It has been shown that TNF-α induces insulin resistance to attenuate insulin receptor signaling and inhibit the activity of this hormone in animal experiments and cell cultures [11, 12]. Eosinophils play an important role in allergic diseases due to MC activation, and they release other inflammatory mediators. Moreover, functional abnormalities of neutrophils, such as phagocytic activity and chemotaxis, have been reported in diabetic patients [7].

Researchers have reported an immune deficiency probably associated with a reduction in insulin secretion that occurs during the diabetic process [13]. In contrast, other researchers have found a direct correlation between hyperglycemia and infection incidence in diabetic patients. Later, still other researchers have reported the effects of platelet activating factor (PAF), leukotriene B (LTB), and some cytokines related with this concept [14, 15]. However, the underlying mechanisms between diabetes mellitus and defects in the immune response have not yet been determined.

Melatonin (Mel) is a powerful antioxidant agent, and its actions are mediated through receptor-mediated and independent mechanisms [16, 17]. Melatonin has been used for the treatment of some diseases related with oxidative stress [18–20]. In particular, the immune-modulatory effects of melatonin have been investigated in many studies and have shown its ability to control the immune response [17, 20, 21]. Additionally, bioregulatory effects of melatonin on peripheral organs such as skin were suggested by contributing to the melatonergic antioxidative system of the skin [22–24].

The hypothesis of the present study on immune regulatory effects control is to find out whether melatonin coordinates inflammation and prevents the destruction of lymphoid tissues in diabetic rats. The aims of the study are to investigate the diabetic effects and the potential protective effects of melatonin on the immune system by means of hematologic values, inflammatory cytokines, and MC activation as well as histopathologic alterations in the spleen, thymus, and lymph nodes of rats with experimentally induced diabetes.

**Material and Methods**

**Animal housing and experimental design**

Thirty-six male Sprague-Dawley rats weighing 180–200 g were used in the study. The experiments were conducted according to the ethical norms approved by the Local Ethics Committee of Ataturk University for Animal Experiments (Decision No. HADYEK 2013-58). All animals were housed under standard laboratory conditions (light period from 06:00 AM to 7:00 PM, 21 ± 2 °C, and relative humidity: 58%). The rats were given water and fed a regular rat diet. All rats were divided into 4 groups as described below:

- The Control (C) group consisted of 9 animals who were not given any treatment throughout the study.
- The Melatonin (Mel) group included 9 animals who were given the melatonin treatment intraperitoneally (IP) at a dose of 10 mg/kg−1 per day for 15 days.
- The Diabetic (DM) group encompassed 9 animals who had been subjected to diabetes with an alloxan injection. After diabetes mellitus had developed, placebo treatment with intraperitoneal 0.5 ml isotonic saline solution (0.09% NaCl) per day was started and given for 15 days.
- The Diabetic-Melatonin (DM-Mel) group consisted of 9 animals who developed diabetes following an alloxan injection. After the diabetes mellitus became evident, melatonin treatment was started and given intraperitoneally at a dose of 10 mg kg−1 per day for 15 days.

**Melatonin preparation and administration**

Melatonin (Sigma Chemical Co. St. Louis, MO, USA) was freshly dissolved in a saline-ethanol (0.01%) mixture and was administered IP at a daily dose of 10 mg/kg body weight according to previous animal studies [20, 25, 26]. Melatonin or the vehicle alone was administered at night for 15 consecutive days.

**Diabetic procedure**

For the DM and DM-Mel groups, experimental diabetes was induced by a single intraperitoneal injection of alloxan monohydrate (Sigma Co., USA) at a dose of 120 mg/kg−1 body weight dissolved in normal saline. To verify diabetes, blood glucose concentrations were measured using blood samples collected from the tail vein with a glucometer and test strips (Accu-Check Active®) at the first hour (before the initiation of trials) and 2 weeks later. The animals were then left alone for 2 weeks to allow for the stabilization of their blood glucose concentrations. On day 14, the animals with a fasting blood glucose level higher than 220 mg/dl were considered diabetic and were therefore included in the study.

**Blood collection and tissue removing procedure**

After 15 days of melatonin treatment (at the end of the study), rats in all the groups were anesthetized with xylazine hydrochloride (10 mg/kg−1) (Rompun, Bayer, Turkey) and ketamine hydrochloride (40 mg/kg−1) (Ketalar, Pfizer, Turkey). Blood samples were individually collected from the heart of each rat, and then the animals were euthanized with an intracardiac thiopental sodium (Pentothal Sodium, Abbott) injection. The lymphoid tissues (spleen, thymus, and lymph nodes) of the euthanized rats were removed for histologic analysis and placed in 10% neutral formaldehyde solution.

**Hematologic and biochemical analysis**

The collected blood samples were centrifuged at 1500 g for 10 min within 1 h after collection to obtain sera samples. The sera were stored in the freezer at −80 °C before they were analyzed. For the hematologic analysis, complete blood counts, white blood cells (WBC), neutrophils (Neut), lymphocytes (Lym), and monocytes (Mon) in the blood samples with ethylenediaminetetraacetic acid (EDTA) were performed with a blood counter (Abacus Junior Vet5, Diatron, Austria).

**Interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) analysis**

Serum IL-1β and TNF-α concentrations were measured using rat-specific sandwich enzyme-linked immunosorbent assay (ELISA) IL-1β and TNF-α immunoassay kits (Invitrogen, CA, USA). Analyses were performed according to the manufacturers’ instructions. Briefly, monoclonal antibody specific for rat IL-1β and TNF-α were coated onto the wells of the micro plate. The samples, including standards of known rat IL-1β and TNF-α contents, control specimens, and sera samples were pipetted into
these groups were evaluated by high-power light microscope (Nikon, Japan). Sections were stained with Crossman-modified Mallory's triple sections in a workstation consisting of a modified light microscope, a motorized stage, and stereo imaging software. The unbiased counting frame and fractionator combination is a stereological method for counting cells in the tissue sections [27, 28]. In this study, unbiased counting frame and fractionator methods were used to estimate the numerical density of enzyme-histochemically stained MCs in the spleen, thymus, and lymph nodes. Each microscope slide was sampled using the fractionator principle of the stereology software. Cells were counted using a 40× Leica Plan Apo objective (NA = 1.40), which allowed accurate recognition. Each MC was counted via the stereology software according to the unbiased counting frame. The numerical densities of the MCs were estimated according to the formula given below:

\[ \text{Nd} = \frac{TM \times CFA}{NSS} \]

where Nd is the MC numerical density, TM is total markers, CFA is the counting frame area (XY) (μm²), and NSS is the number of sampling sites.

**Statistical analysis**

The statistical evaluation of present study was performed using the Statistical Package for the Social Sciences (SPSS) Version 17.0 (IBM Inc. NY, USA). The comparisons of the groups according to hematologic values, cytokine concentrations, and stereological data were analyzed by one-way ANOVA followed by Duncan post hoc test (p < 0.05). All values are expressed as mean±standard deviation.

**Results**

**Hematologic values**

In the hematologic analysis of white blood cell parameters, there was a significant increase in the WBC counts of the DM group compared with the Control group (p < 0.05). Additionally, the Neut counts of the DM group tended to be increased compared with the Control group (p < 0.05). At the same time, WBC, Mon, and Neut counts were significantly decreased in the DM-Mel group when compared with the DM group (p < 0.05), and there were no significant difference in Lym counts compared with the Control group (p > 0.05). Additionally, the parameters for WBCs, Mons, and Neuts significantly decreased in the Mel group (p < 0.05), and the Lym count decreased insignificantly compared with the Control group (p > 0.05). The comparisons of WBC, Lym, Mon, and Neut parameters are summarized in Table 1.

**Serum cytokine concentration**

Serum IL-1β and TNF-α analyses revealed an increase in the concentrations of the DM group compared with the Control group. However, the IL-1β concentration slightly decreased in the DM-Mel group compared with the DM group (p < 0.05), but TNF-α concentration did not change in the DM-Mel group (p > 0.05). In addition, there was little increase in the levels of IL-1β and TNF-α concentrations in the Mel group (p > 0.05). The IL-1β and TNF-α concentrations and the statistical comparisons among the groups are presented in Fig. 2.

**Histopathologic findings**

In the histopathologic analysis of the spleen and thymus for all groups, the animals in the Control and Mel groups had normal parenchyma and stroma. Additionally, sections from the DM group had severely condensed cells and fibrotic parenchyma and capsules. Conversely, the DM-Mel group showed less fibrosis and fewer condensed cells compared with the DM group (Table 1 and Fig. 3).
Histopathologic analysis of the lymph nodes revealed normal histologic features in the control group section, and similarly normal histologic structures were observed in lymph node tissues of the animals in the Mel group except for the negligible dilatation of the medullary sinuses. Histopathologic analysis of DM group specimens also showed severely condensed cells, enlargement of the tertiary cortical nodules and medullary cords, and large numbers of free macrophages in the medullary sinuses; however, these pathologies were lessened by the melatonin treatment (Fig. 3). Histopathologic grades of all groups are presented in Table 1.

Stereologic estimation of MC density

Enzyme histochemical esterase staining for MCs revealed that the highest MC density of the spleen was found in rats of the DM group, but rats in the DM-Mel group had a lower MC density ($p < 0.05$). The rats in the control and Mel groups had lower MCs numbers in their spleen tissue ($p > 0.05$).

Stereologic estimation of thymus MC densities indicated a significant decrease in MC densities of the Mel group compared with other groups ($p < 0.05$). MC densities of the DM and DM-Mel groups increased compared with the control group, and there was no statistically significant difference ($p > 0.05$).

Estimation of MC densities of lymph node tissue revealed an inhibitory effect of melatonin on MC distribution. A larger number of MC was observed in the Control and DM groups compared with the other groups ($p < 0.05$). Dramatically, the lowest number of MCs was observed in the DM-Mel groups. Stereologic estimation of MC numbers per 10000 $\mu$m$^2$ area and comparisons among groups are presented in Fig. 4, 5.

Discussion

Evidence of immune response alterations in diabetes has been reported in several studies [3, 9] regarding pathologic immune activity and inflammatory cell accumulations. According to some researchers [20, 29, 30], diabetes mellitus is similar to some organ-specific autoimmune diseases in that it results from a dysregulation of immune responses. The present study was designed to investigate the potential regulatory effects of melatonin on the immune system, including cytokine activation, hematologic parameters, mast cell activation, and destruction of lymphoid organs in rats with experimentally induced diabetes.
Hematologic parameters such as the neutrophil count are an indicator of injurious stimuli and are mostly part of an inflammatory response. In the present study, leukocytosis and elevated neutrophil counts were detected in the hematologic profile of the Diabetic group, while melatonin treatment induced a significant decrease in WBC counts. The increase in WBC counts of diabetes was associated with the pathophysiology of the diabetic process [31], whereas melatonin treatment can attenuate the hematologic parameters against the diabetic injury [17, 32, 33]. These results are in agreement with previous studies, which have suggested a decrease in the total leukocyte count following melatonin treatment [34, 35]. The underlying mechanism of this melatonin-induced decrease in WBC count has not been clarified. However, some mechanisms are responsible for this action. The first possible mechanism is that melatonin may have inhibited hematopoiesis in either the bone marrow [35] or lymphatic

<table>
<thead>
<tr>
<th>Groups</th>
<th>Spleen Condensed cell density</th>
<th>Parenchymal and capsular fibrosis</th>
<th>Thymus Cortex/medulla ratio</th>
<th>Enlargement in cords</th>
<th>Lymph Condensed cell density</th>
<th>Enlargement in cords</th>
<th>PMNL density</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>0.399</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Mel</td>
<td>−</td>
<td>+</td>
<td>0.475</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>DM</td>
<td>+ + +</td>
<td>+</td>
<td>0.491</td>
<td>+ + +</td>
<td>+</td>
<td>+ + +</td>
<td>+</td>
</tr>
<tr>
<td>DM-Mel</td>
<td>+ +</td>
<td>+</td>
<td>0.396</td>
<td>+ +</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Each criterion was scored as: −; normal, +; minimal change, + +; mild change, and + + +, severe change.

Table 1 Semi-quantitative analysis of the histopathological grades of the spleen, thymus, and lymph node tissues for all groups.

Fig. 3 Illustration of spleen, thymus, and lymph node tissues for all groups. CV: Central vein; WP: White pulp; RP: Red pulp; Cx: Cortex; MD: Medulla; LF: Lymph follicle; Cr: Lymphatic cords. Arrows: condensed cells, Crossman-modified Mallory’s triple staining. (Color figure available online only).
tissue [36] by direct action to the production of leukocytes [37]. The other possible mechanism is that melatonin may protect hematopoietic systems by scavenging free radicals due to its antioxidant features [17]. The present research showed that melatonin treatment significantly decreased leukocytogenesis in diabetic patients.

It is important to identify the pathogenic relationship between diabetes mellitus and cytokine activation. There is evidence that the cytotoxic actions of IL-1, TNF-α, and IFN-γ have been detected in islets cells of diabetic patients [9]. Increased inflammation and MC infiltration had an essential role in obesity and its associated complications. Shi and Shi have suggested that MCs may interact with inflammatory and noninflammatory cells by releasing inflammatory mediators [30]. However, inflammatory mediators originate from many cells such as macrophages and adipocytes. Additionally, it is reported that the expression of
TNF-α by adipocytes provokes obesity and can lead to insulin resistance by interfering with insulin receptor tyrosine kinase activity [3] and polymorphisms in the promoters of TNF-α and IL-6, which were found to be associated with diabetes [11]. Previous studies have reported direct evidence for the process of such a cytokine immunoregulatory balance in the avoidance of autoimmune diabetes [3, 38]. However, Rodriguez-Reynoso et al. reported the inhibitor effect of melatonin on TNF-α level depends on the energetic status of the liver [39]. Furthermore, numerous studies have shown the immune-modulatory action of melatonin in many diseases, including diabetes [17, 20]. The findings of the present study revealed increased cytokine activation in the diabetic process and the treatment with melatonin slightly modulate the immune response of diabetes due to the possible immunomodulatory action of melatonin.

Mast cells have been reported to be potent effectors of the immune system in many autoimmune diseases, such as systemic lupus erythematosus, multiple sclerosis, and T1DM [40]. MCs settle in connective tissues throughout the body, including the lymphoid organs [41], which are derived from hematopoietic CD34+ stem cells. MCs can produce many immune mediator substances and cell signaling molecules that are responsible for coordinating immune responses during inflammation [8]. Also, there is an interaction between MCs and T cells in T cell-related immune activation [42]. Previous studies have reported both an increase [43] and a decrease [7] in MC densities in diabetes mellitus, and these changes were associated with diabetes type, complications of diabetes, and applied diabetic agents [30]. Cicler et al. reported that melatonin treatment can decrease mast cells in the dermis in water avoidance stress-induced rats [44]. A decrease in melatonin levels has also been observed in many diseases, including Alzheimer’s disease, a periodontitis rat model, and a diabetes rat model [25, 45], all of which would be logically related with direct or indirect inhibitory action of melatonin on mast cells. The findings of the present study are in agreement with the literature that there were higher densities of MCs in the all-lymphoid organs. These results revealed the role of MCs in diabetic inflammation by T-cell mediated response; however, their role in diabetes progression remains unclear.

The histopathologic results of the present investigation revealed that melatonin treatment protects the lymphoid organs (lymph node, spleen, and thymus) from diabetic effects. Many studies have indicated that melatonin can decrease the free radical load via the underlying mechanism by which melatonin exerts its immune-potentiating action [19, 46, 47]. Melatonin MT1 and MT2 receptors are located on lymphoid organs, including the thymus and the spleen [47, 48], as well as the bursa of Fabricious in bird species, which suggests that melatonin might have a physiological process of lymphocyte regulation and immune response [48]. Also, the immunomodulatory action of melatonin has been summarized in many reviews regarding its importance from a systemic point of view as well as for its possible therapeutic relevance to cell protection and mitochondrial function [32, 49, 50]. These studies are in agreement with our study and have supported that the diabetic process may lead to pathologic processes by several mechanism, whereas melatonin treatment enhanced the cell defense due to its ability to restore antioxidants. Additionally, melatonin decreased the proliferation of splenocytes and type 1 helper cells [17]. In conclusion, the characteristics of immune response and MC-mediated activation in diabetic pathogenesis underline the mechanisms by which this inflammation contributes to many tissues, including lymphoid organs. In addition, melatonin could be a candidate for the design of novel therapies to moderate diabetic inflammation through its immune-modulatory and/or antioxidant properties.

Conflict of Interest

The authors declare no conflict of interest.

Affiliations

1 Department of Biochemistry, Faculty of Veterinary Medicine, University of Ataturk, Erzurum, Turkey
2 Department of Histology and Embryology, Faculty of Veterinary Medicine, University of Ataturk, Erzurum, Turkey
3 Department of Physiology, Faculty of Veterinary Medicine, University of Ataturk, Erzurum, Turkey
4 Department of Histology and Embryology, Faculty of Medicine, University of Balikesir, Balikesir, Turkey
5 Department of Physiology, Faculty of Medicine, University of Balikesir, Balikesir, Turkey
6 Department of Biochemistry, Faculty of Medicine, University of Ataturk, Erzurum, Turkey

References

16 Afzal R. Melatonin: Miracles far beyond the pineal gland. Indian J Endocrinol Metab 2012; 16: 672
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.